Twist Bioscience (TWST) Capital Expenditures (2017 - 2026)

Twist Bioscience (TWST) has reported Capital Expenditures for 10 consecutive years, with $9.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Capital Expenditures rose 6.52% year-over-year to $9.8 million in Q2 2026; TTM through Jun 2026 was $40.1 million, a 127.83% increase from a year earlier, with the FY2025 full-year figure at $28.0 million, up 451.69% from the prior year.
• Capital Expenditures was $9.8 million for Q2 2026 at Twist Bioscience, up from $7.9 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $40.6 million in Q2 2022 and troughed at $603000.0 in Q1 2024.
• A 5-year average of $9.9 million and a median of $8.5 million in 2023 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures plunged 93.34% in 2024 and jumped 849.74% in 2025, its largest moves.
• Over 5 years, Capital Expenditures stood at $11.8 million in 2022, then sank by 87.26% to $1.5 million in 2023, then soared by 50.6% to $2.3 million in 2024, then jumped by 339.77% to $10.0 million in 2025, then fell by 2.12% to $9.8 million in 2026.
• The last three Capital Expenditures figures came in at $9.8 million (Q2 2026), $7.9 million (Q1 2026), and $10.0 million (Q4 2025), per Business Quant data.